Latest Articles
MTFR2 promotes endometrial carcinoma cell proliferation and growth via the miR-132-3p /PI3K/Akt signaling pathway - Frontiers
MTFR2 promotes endometrial carcinoma cell proliferation and growth via the miR-132-3p /PI3K/Akt signaling pathway Frontiers
Published: Nov. 25, 2024, 3:55 p.m.
A Case of Early-Stage Lower Uterine Segment Carcinoma With Hysteroscopic Observation of Visual Changes Induced by a Gonadotropin-Releasing Hormone (GnRH) Antagonist - Cureus
A Case of Early-Stage Lower Uterine Segment Carcinoma With Hysteroscopic Observation of Visual Changes Induced by a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cureus
Published: Nov. 23, 2024, 11:41 a.m.
Undifferentiated Endometrial Carcinoma Occurred During Perimenopausal Hormone Therapy: A Case Report and Literature Review - Frontiers
Undifferentiated Endometrial Carcinoma Occurred During Perimenopausal Hormone Therapy: A Case Report and Literature Review Frontiers
Published: Oct. 18, 2024, 10:58 a.m.
Effect of endometriosis on prognosis of ovarian clear cell carcinoma: a 10-year retrospective study - Frontiers
Effect of endometriosis on prognosis of ovarian clear cell carcinoma: a 10-year retrospective study Frontiers
Published: Oct. 17, 2024, 10:59 a.m.
Retrospective, Observational, Pilot Study to Assess the Safety and Efficacy of Goel’s Technique of Laparoscopic Hysterectomy in Endometrial Carcinoma - Cureus
Retrospective, Observational, Pilot Study to Assess the Safety and Efficacy of Goel’s Technique of Laparoscopic Hysterectomy in Endometrial Carcinoma Cureus
Published: Oct. 15, 2024, 12:12 p.m.
Clear Cell Carcinoma Arising From Adenomyotic Cyst: A Case Report - Cureus
Clear Cell Carcinoma Arising From Adenomyotic Cyst: A Case Report Cureus
Published: Oct. 15, 2024, 6:37 a.m.
Incarcerated Incisional Hernia: An Unusual Presentation of Metastatic Endometrial Carcinoma - Cureus
Incarcerated Incisional Hernia: An Unusual Presentation of Metastatic Endometrial Carcinoma Cureus
Published: Oct. 15, 2024, 5:32 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress
Published: June 24, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay
Published: June 21, 2024, 7 a.m.
Androgen-responsive FOXP4 is a target for endometrial carcinoma | Communications Biology - Nature.com
Androgen-responsive FOXP4 is a target for endometrial carcinoma | Communications Biology Nature.com
Published: June 18, 2024, 7 a.m.
Link copied to clipboard!